Playback speed
10 seconds
SARS-CoV-2 CRISPR Screen Analysis: Why Is Clinical Presentation so Variable from Asymptomatic to Death? Can SARS-CoV-2 Therapeutics Be Developed Against Host Targets, and What Is the Role of HMGB1 in Infection?
By
Columbia University's Zuckerman Institute
FEATURING
Craig Wilen
By
Columbia University's Zuckerman Institute
FEATURING
Craig Wilen
1,579 views
September 17, 2020
Login to view comments.
Click here to Login